Author:
Martín Miguel,García-Puche José Luis,Casado Antonio,Talavera María del Carmen,Menéndez María Dolores,Alba Emilio,Pelegrí Amadeu,Balil Ana,Rodríguez-Lescure Álvaro,Casinello Javier,Lozano Ana María,Pérez-Carrión Ramón,Virizuela José Antonio,Aranda Enrique,Oltra Amparo,Díaz-Rubio Eduardo
Publisher
Springer Science and Business Media LLC
Reference19 articles.
1. Hortobagyi GN, Piccart-Gebhart MJ. Current management of advanced breast cancer. Semin Oncol 1996;23 Suppl 11:1–5.
2. Martin M, Casado A, Llorente L, et al. Long-Term Disease-Free Survival in Disseminated Breast Cancer Patients Treated with Conventional and High-Dose Chemotherapy: Predictive Factors and Therapeutic Implications. ESO Scientific Updates, Vol. 3. Dose and Timing: The Pillars of Successful Chemotherapy. Rosti G. Amsterdam: Elsevier Science; 1998.
3. Greenberg PAC, Hortobagyi GN, Smith TL, et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996;14:2197–205.
4. Nabholtz JM, Mackey JR, Smylie M, et al. Phase II Study of Docetaxel, Doxorubicin, and Cyclophosphamide as First-Line Chemotherapy for Metastatic Breast Cancer. Clin Oncol 2001;19:314–21.
5. Gianni L, Munzone E, Capri G, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995;13:2688–99.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献